【レポートの概要（一部）】
1. Report Overview
1.1 Biosimilars Overview
1.2 Biosimilars Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain
2. An Introduction to Biosimilars and Biosimilar Drug Development
2.1 What are Biologics?
2.1.1 Biologics can be Very Effective but also Very Expensive
2.1.2 Brief History of Biological Drug Development
2.1.3 Why are Biologics the Most Lucrative Products in the Global Pharmaceutical Market?
2.2 What are Biosimilars?
2.3 Brief History of Biosimilars
2.4 What are Interchangeable Biological Products and how do They Differ from Biosimilars?
2.4.1 FDA Guidelines on Prescription of Interchangeables vs Biosimilars
2.4.2 Where does the EMA Stand with Regard to Interchangeables?
2.4.3 Where do the EU5 and other European Countries Stand with Regard to Automatic Substitution?
2.4.4 Why Would Nations Oppose Automatic Substitution of Reference Biologics with Biosimilars?
2.5 Main Segments of the Overall Biosimilars Market
3. The Global Biosimilars Market 2016-2026
3.1 The Global Biosimilars Market
3.2 Biosimilars as a Share of the Biologics Market, 2014
3.2.1 Seven of the Top Ten Best-Selling Drugs are Biologics
3.2.2 Outlook for the Overall Biologics Market
3.3 Global Biosimilars Market Forecast, 2016-2026
3.4 What will Drive Growth in the Biosimilars Market?
3.4.1 Biosimilars Can Bring about Savings of Billions – $44bn for the US by 2024 and $33bn for Europe by 2020
3.4.2 Over $67bn Worth of Biologic Patents due to Expire by 2020
3.4.3 US Approves First Biosimilar – Zarxio. Will this Open the Floodgates? Interchangeability Can also Drive Growth
3.4.4 Other Developed and Emerging Markets Will also Provide Opportunities for Growth
3.4.5 Competitive Landscape Emerging for Biosimilars
3.5 What Factors can Restrain Sales Growth in the Biosimilars Market?
3.5.1 Complexity of Biologics Means that Biosimilar Development Faces Many Challenges
3.5.2 Opposition from Originator Companies and Patent Issues
3.5.3 Fragmentation in the Market as Many Companies Chase the Same Targets
3.5.4 The Threat of Biobetters and Next-Generation Biologics
3.6 Summary of the Drivers and Restraints for the Global Biosimilars Market
3.7 Global Biosimilars Market Forecast by Submarket, 2016-2026
3.7.1 Leading Segments in the Biosimilars Market
3.7.2 How Will the Composition of the Market Change Over the Next Ten Years?
4. Outlook for Biosimilars in Leading Developed Markets, 2016-2026
4.1 The Leading National Biosimilar Submarkets
4.2 National Submarket Forecasts 2016-2026
4.3 How will the Regional Composition of the Global Market Change from 2016-2026?
4.4 US Biosimilars Market Outlook 2016-2026
4.4.1 Status of the US Market in 2014 and 2015
4.4.2 FDA Finalises Three New Guidelines on 351(k) Applications in April 2015
4.4.2.1 The History of the US’ Biosimilar Guidelines
4.4.3 FDA Finally Releases Guidance on Biosimilar Naming in August 2015
4.4.4 Individual States Can Pass their Own Biosimilar Substitution Laws
4.4.5 US Biosimilars Market Forecast 2016-2026
4.5 The EU Biosimilar Market: History and Current Status
4.5.1 History of EMA Guidelines and Updates
4.5.2 Biosimilar Uptake in the Europe Varies between Nations
4.5.3 European Biosimilars Market Forecast, 2016-2026
4.5.4 Inflectra and Remsima in Europe – Demonstrates a Path for Other Biosimilar mAbs
4.5.5 German Biosimilar Market Outlook, 2016
4.5.5.1 German Biosimilar Market Forecast, 2016-2026
4.5.6 French Biosimilars Market Outlook, 2016
4.5.6.1 Biosimilar Substitution Passed but Requires Decrees to Come into Effect, Expected Sometime This Year
4.5.6.2 French Biosimilar Market Forecast, 2016-2026
4.5.7 UK Biosimilar Market Outlook, 2016
4.5.7.1 UK Biosimilar Market Forecast, 2016-2026
4.5.8 Italian Biosimilars Market Outlook, 2016
4.5.8.1 Italian Biosimilars Market Forecast, 2016-2026
4.5.9 Spanish Biosimilars Market Outlook, 2016
4.5.9.1 Spanish Biosimilar Market Forecast, 2016-2026
4.5.10 Biosimilar Regulation in Japan and Currently Approved Biosimilars
4.5.10.1 Differences between the European and Japanese Guidelines
4.5.10.2 Currently Approved Biosimilars in Japan
4.5.10.3 Japanese Biosimilar Market Forecast, 2016-2026
5. Outlook for Biosimilars in Emerging Markets, 2016-2026
5.1 China and India Lead Biosimilar Revenues
5.2 Leading Emerging Biosimilar Markets Forecast, 2016-2026
5.3 Chinese Biosimilars Market Outlook, 2016
5.3.1 China Publishes Final Guidelines for Biosimilars
5.3.2 Biosimilars Account for less than Half of Biotech Revenues in China
5.3.3 Chinese Biosimilars Market Forecast, 2016-2026
5.4 Indian Biosimilars Market Outlook, 2016
5.4.1 CDSCO Guidelines Released in 2012
5.4.2 Indian Biosimilars Market Forecast, 2016-2026
5.5 South Korea’s Established Biosimilar Guidelines
5.5.1 Currently Approved Biosimilars in South Korea, 2016
5.5.2 South Korean Biosimilars Market Forecast, 2016-2026
5.6 Russian Biosimilars Market Outlook and Forecast, 2016-2026
5.7 Brazilian Biosimilar Regulation
5.7.1 Government Eager to Promote Biosimilar Development, and Two Major Conglomerates, Bionovis and Orygen, are Racing to Produce Biosimilars
5.7.2 Brazilian Biosimilars Market Forecast, 2016-2026
6. Biosimilar Monoclonal Antibodies: Submarket Forecast and Pipeline, 2016-2026
6.1 MAbs as Part of the Overall Biologics Market in 2014
6.2 Monoclonal Antibodies (mAbs): Largest Biologic Submarket, with Individual Drugs Accumulating Multi-Billion Dollar Revenues
6.3 Biosimilar Monoclonal Antibodies Market and Submarkets Forecast, 2016-2026
6.4 Drivers for the Biosimilar Monoclonal Antibodies Market
6.4.1 New Launches of Biosimilar mAbs in Developed and Emerging Markets
6.4.2 Rising Incidence of Cancer will Drive Demand
6.4.3 The Need for Lower Cost Therapies
6.4.4 Partnering to Launch Biosimilar mAbs
6.5 Restraints for the Monoclonal Antibodies Market
6.5.1 Novel mAb Developers Choosing to Develop Biobetters and Next-Generation Therapies in Face of Biosimilar Competition
6.5.1.1 Hope for Biosimilars when Competing Against Next-Generation Therapies
6.5.2 Challenges in Antibody Development and Manufacturing
6.5.3 Patent Issues, Market Fragmentation and Perception of Biosimilars
6.6 Leading Targets for Biosimilar Development, 2016-2026
6.7 Biosimilar Rituximab
6.7.1 Rituxan: The First Anti-Cancer mAb
6.7.2 Approved Biosimilars and Rituxan Patent Expiry
6.7.2.1 Reditux (Dr. Reddy’s Laboratories): First Biosimilar Rituximab
6.7.2.2 MabTas (Intas Pharmaceutical): Another Indian Biosimilar
6.7.2.3 AcellBia (Biocad): The Leading Biosimilar Rituximab
6.7.2.4 Kikuzubam (PROBIOMED) – Faced Challenges
6.7.3 Biosimilar Rituximab Pipeline, 2016-2026
6.7.3.1 Terminated Developments
6.7.3.2 GP2013 (Sandoz): One of the Biggest Names in the Biosimilar Industry Throws its Hat into the Ring with Advanced Stage Candidate
6.7.3.3 BI 695500 (Boehringer Ingelheim)
6.7.3.4 MabionCD20 (Mabion): Focusing on Markets with High Demand
6.7.3.5 CT-P10 (Celltrion)
6.7.3.6 PF-05280586 (Pfizer)
6.7.4 Biosimilar Rituximab: Revenue Forecast 2016-2026
6.8 Biosimilar Infliximab
6.8.1 Remicade: Second Only to Humira
6.8.2 Approved Biosimilars and Remicade Patent Expiry: Uncertainty in the US after FDA Rejection
6.8.2.1 Inflectra and Remsima (Hospira and Celltrion)
6.8.2.2 Celltrion Speeds Ahead with US FDA Filing, and Inflectra Approved in Australia and Canada
6.8.2.3 Inflimab and BOW015 (Epirus Biopharmaceuticals and Ranbaxy Laboratories)
6.8.3 Biosimilar Infliximab Pipeline, 2015-2026
6.8.3.1 SB2 (Samsung Bioepis): Has been Filed for EU Approval and Shows Positive Phase 3 Results
6.8.3.2 NI-071 (Nichi-Iko): Advanced Stages
6.8.3.3 ABP 710 (Amgen) and BX2922 (BioXpress Therapeutics)
6.8.4 Biosimilar Infliximab: Revenue Forecast 2016-2026
6.9 Biosimilar Trastuzumab
6.9.1 Herceptin: Another Jewel in Roche’s Cancer mAb Portfolio
6.9.2 Approved Biosimilars and Herceptin Patent Expiry
6.9.2.1 Hertraz and CanMab (Mylan and Biocon): The First to Win Approval
6.9.2.2 Herzuma (Celltrion)
6.9.3 Biosimilar Trastuzumab Pipeline, 2015-2026
6.9.3.1 BCD-022 (Biocad): Leading Biosimilar Rituximab Developer Tries its Hand at Trastuzumab
6.9.3.2 ABP 980 (Amgen and Allergan): Phase 3
6.9.3.3 PF-05280014 (Pfizer): Phase 3
6.9.3.4 SB3 (Samsung Bioepis) and BX2318 (BioXpress Therapeutics)
6.9.4 Biosimilar Trastuzumab: Revenue Forecast 2016-2026
6.10 Biosimilar Adalimumab
6.10.1 Humira – The World’s Best-Selling Prescription Drug
6.10.2 Approved Biosimilars and Humira Patent Expiry
6.10.2.1 Exemptia (Zydus Cadila): The First Biosimilar Adalimumab
6.10.3 Biosimilar Adalimumab Pipeline, 2015-2026
6.10.3.1 ABP 501 (Amgen and Allergan): Positive Phase 3 Results Released
6.10.3.2 GP2017 (Sandoz): Phase 3
6.10.3.3 BI 695501 (Boehringer Ingelheim)
6.10.3.4 SB5 (Samsung Bioepis): Phase 3 Results
6.10.4 Biosimilar Adalimumab: Revenue Forecast 2016-2026
6.11 Biosimilar Bevacizumab
6.11.1 Avastin: High Revenues and Late Patent Expiry
6.11.2 Biosimilar Bevacizumab Pipeline, 2016-2026
6.11.2.1 BCD-021 (Biocad)
6.11.2.2 ABP 215 (Amgen and Allergan): Positive Phase 3 Results
6.11.2.3 BI 695502 (Boehringer Ingelheim): Phase 3
6.11.2.4 PF-06439535 (Pfizer): Phase 3
6.11.3 Biosimilar Bevacizumab: Revenue Forecast, 2016-2026
7. Biosimilar Fusion Proteins: Submarket Forecast and Pipeline, 2016-2026
7.1 Scientific Background
7.2 Differentiating Fusion Proteins
7.3 Fusion Proteins as Part of the Overall Biologics Market
7.4 Biosimilar Fusion Proteins Market Forecast, 2016-2026
7.5 Biosimilar Etanercept, 2016-2026
7.5.1 Enbrel is the Leading Fusion Protein
7.5.2 Enbrel Granted Extended Patent Protection in the US, Patent has Expired in EU
7.5.3 Multiple Biosimilars Available in Emerging Markets
7.5.3.1 Brenzys / SB4 (Merck and Samsung Bioepis): First Product Approval to Result from Biosimilar Collaboration
7.5.3.2 Yi Sai Pu (Shanghai CP Guojian Pharmaceutical) and Qiangke (Shanghai Celgen Biopharmaceutical)
7.5.3.3 Etacept (Cipla) and Intacept (Intas Pharmaceuticals)
7.5.3.4 Davictrel / HD-203 (Hanwha Chemical and Merck KGaA)
7.5.4 Biosimilar Etanercept Pipeline
7.5.5 GP2015 (Sandoz)
7.5.5.1 Sandoz Goes in Early: FDA Accepts Application for GP2015, Despite the Fact that Enbrel Patents are not due to Expire any time Soon
7.5.6 SB4 (Samsung Bioepis): EMA Accepts Application
7.5.6.1 Samsung Bioepis Releases Positive Phase 3 Data for SB4
7.5.7 CHS-0214 (Coherus Biosciences and Baxter)
7.5.8 TuNEX / ENIA11 (Mycenax Biotech / TSH Biopharm Corp): Phase 3 in Taiwan
7.5.9 LBEC0101 (LG Life Sciences): Phase 3
7.5.10 Biosimilar Etanercept: Revenue Forecast 2016-2026
7.6 Eylea and Biosimilar Aflibercept
7.7 Orencia and Biosimilar Abatacept
8. Biosimilar Insulin Submarket Outlook, 2016-2026
8.1 Insulin as Part of the Biological Drug Sector
8.2 30 Million People Expected to be Diagnosed with Diabetes by 2030
8.3 Approved Insulin Biosimilars
8.4 Abasaglar / Basaglar / Insulin Glargine BS – The First Insulin Biosimilars to be Approved in Developed Markets
8.5 EMA Releases Finalised Insulin Biosimilars Guideline
8.6 Basaglar Delayed in the US until End of 2016
8.7 Biosimilar Insulin Market and Submarkets Forecast, 2016-2026
8.8 Biosimilar Human Insulin Submarket, 2016-2026
8.8.1 A Submarket Mostly Restricted to Emerging Markets?
8.8.2 Biosimilar Human Insulin in China
8.8.3 Biosimilar Human Insulin in India
8.8.3.1 Wockhardt and Biocon – Given up on their Desire to Target the US and Europe?
8.8.4 Biosimilar Human Insulin in Russia
8.8.5 Biosimilar Human Insulin Submarket Forecast, 2016-2026
8.9 Biosimilar Insulin Analogues Submarket, 2016-2026
8.9.1 Available Biologic Insulin Analogues – Sanofi’s Lantus Tops Revenues
8.9.2 Insulin Glargine in the Main Biosimilar Target
8.9.2.1 Limited Development for the Other Targets
8.9.3 Insulin Market Leaders are Developing Ultra-Rapid Acting Insulin Analogues
8.9.3.1 Ultra-Long Acting Insulin also in Development
8.9.4 Mylan Partners with Biocon for Insulin Analogues
8.9.5 Biosimilar Insulin Analogue Revenue Forecast, 2016-2026
8.10 Biosimilar Insulin Glargine
8.10.1 Biosimilars in India and China
8.10.2 Biosimilar Insulin Glargine Pipeline
8.10.2.1 MK-1293 (Merck / Samsung Bioepis)
8.10.2.2 Mylan’s Insulin Glargine (Mylan and Biocon)
8.10.3 Biosimilar Insulin Glargine: Revenue Forecast, 2016-2026
8.11 Biosimilar Insulin Lispro
8.11.1 One Biosimilar is Currently Available – Prandlin
8.11.2 Much Smaller Pipeline than for Insulin Glargine
8.11.3 Biosimilar Insulin Lispro: Revenue Forecast, 2016-2026
9. Biosimilar Erythropoietins Submarket Outlook, 2016-2026
9.1 Three Products Lead the Biologic EPO Therapy Market
9.2 Safety Concerns for Erythropoietin-Stimulating Agents
9.3 The Challenge from Oral Therapies is Coming
9.4 Treating Anaemia in Patients with CKD – the Leading Use of EPO Therapies
9.5 Biosimilar Epoetin Approvals in Europe
9.6 Epoetin Alfa Pipeline for the European Market
9.7 Trends in Uptake for Biosimilar Epoetins in Europe
9.8 Epoetin Alfa Pipeline for the US – Companies Preparing for Launch
9.8.1 Pfizer’s Retacrit Delayed after Response Letter from FDA
9.8.2 Binocrit / HX575 has Completed Trials
9.9 Biosimilar Epoetin in Japan
9.10 Biosimilar Epoetin in South Korea
9.11 Biosimilar Epoetin in India and China
9.12 Second-Generation EPO Biosimilars
9.13 No Mircera Biosimilars in Clinical Development
9.14 Biosimilar EPO Market Forecast, 2016-2026
10. Biosimilar G-CSF Submarket Outlook, 2016-2026
10.1 Amgen Leads the Branded Biologic G-CSF Market
10.2 Teva Launches Long-Acting Pegfilgrastim
10.3 Selected Filgrastim Biosimilars Approved Worldwide
10.3.1 The European G-CSF Biosimilars Market
10.3.1.1 Trends in Biosimilar Uptake Across Europe
10.3.2 Tevagrastim (Teva): The First Biosimilar in Europe, Launched as Granix in the US
10.3.3 Nivestim (Hospira – Pfizer)
10.3.4 Zarzio (Sandoz): The Most Prescribed Biosimilar Therapy in Europe
10.3.5 Zarxio Becomes the First Biosimilar to be Approved in the US, Launched in September
10.3.6 Apotex: FDA has Accepted Applications for both its Biosimilar Filgrastim, and its Biosimilar Pegfilgrastim
10.3.7 Multiple Launches in Japan in Recent Years
10.3.8 Biosimilar Filgrastim and Pegfilgrastim in India
10.3.9 Biosimilars in Russia, China and Other Emerging Markets
10.4 Biosimilar G-CSF Market Forecast, 2016-2026
11. Biosimilar Interferons Submarket Outlook, 2016-2026
11.1 Interferons: Key Antiviral and MS Therapies Since the 1990s
11.2 Leading Interferon Brands
11.3 Competition for the Multiple Sclerosis Market – Challenges for Interferon Beta Therapies
11.4 All-Oral Regimens will Challenge Interferon Alfa Therapy
11.4.1 However Oral Therapies will be Expensive
11.5 There are no Approved Biosimilars in Developed Markets
11.6 Biosimilar Interferon Market Forecast, 2016-2026
11.7 Biosimilar Interferon Alfa
11.7.1 Biosimilar Interferon Alfa – a Common Target in Developing Countries, Leading to Fragmented Markets
11.7.2 Biosimilar Peginterferon Alfa
11.7.3 Hepatitis Treatment Rates are Low
11.7.4 Biosimilar Interferon Alfa Submarket Forecast, 2016-2026
11.8 Biosimilar Interferon Beta
11.8.1 Biosimilars are Well-Established in Emerging Markets
11.8.2 Biosimilar Interferon Beta Pipeline
11.8.3 EMA Guidance
11.8.4 Long-Acting Interferon Beta
11.8.5 Biosimilar Interferon Beta Submarket Forecast, 2016-2026
12. Biosimilar Recombinant Hormones Submarket Outlook, 2016-2026
12.1 Human Growth Hormone: First Extracted in 1958
12.2 Biologic Growth Hormone Market in 2014 – Novo Nordisk and Pfizer Dominate
12.2.1 Novo Nordisk Aiming to Retain Dominance Through FlexPro Device and NN8640 Somatropin Candidate
12.3 Biosimilar Growth Hormones
12.3.1 Omnitrope – Well Established in Developed Markets
12.4 Multiple Biosimilars Available Worldwide
12.4.1 Biosimilars Growth Hormones Outside of Asia
12.4.2 Biosimilar Growth Hormones in Asia
12.4.3 Biosimilar Uptake Varies by Region
12.5 Biosimilar Growth Hormones Market Forecast, 2016-2026
12.6 Fertility Hormones
12.6.1 Two Products Lead the Branded Fertility Hormone Market
12.6.2 Long-Acting Follicle Stimulating Hormone (FSH)
12.6.3 Branded Fertility Hormones Market Outlook
12.6.4 Available Biosimilar Fertility Hormones
12.6.5 Biosimilars Approved in Europe
12.6.5.1 Ovaleap (Teva)
12.6.5.2 Befomla (Finox Biotech) Approved in Europe, Undergoing Phase 3 for US
12.6.6 Rising Infertility to Drive Demand to 2026
12.6.7 Biosimilar Fertility Hormones Market Forecast, 2016-2026
13. Biosimilars: Qualitative Analysis and Industry Trends
13.1 SWOT Analysis of the Biosimilars Market
13.2 Biosimilars Market: Strengths
13.2.1 Biosimilars Can Offer Huge Cost Savings
13.2.2 The US has Finally Joined the Global Biosimilars Market
13.2.3 Biosimilars are Already Well-Established in Many National Markets
13.2.4 Outsourcing Offers the Chance for Further Cost Savings
13.3 Biosimilars Market: Weaknesses
13.3.1 Biosimilars are High Cost to Develop and Manufacture
13.3.2 Complexity Means that Development Timelines are Long
13.3.3 Uptake for Biosimilars Varies and is Low in Some Regions
13.4 Biosimilars Market: Opportunities
13.4.1 Blockbuster Biologics Face Patent Expiry
13.4.2 Rising Disease Prevalence
13.4.3 Licensing Agreements for Biosimilars
13.5 Threats
13.5.1 Biobetters and Next-Generation Biologics
13.5.2 Patent Issues and Product Life Cycle Management from Originator Companies
13.5.3 Fragmentation in the Market
13.5.4 Long Market and Data Exclusivity Periods
13.5.5 Biosimilars Require Marketing and Education
14. Research Interviews from Our Survey
14.1 Interview with PROBIOMED
14.1.1 Introduction to PROBIOMED
14.1.2 PROBIOMED’s Most Prominent Biosimilars and its Future Pipeline
14.1.3 Withdrawal of Kikuzubam and Changes in Mexican Biosimilar Regulation
14.1.4 On Standing out from the Competition
14.1.5 On How the Biosimilars Market will Develop over the Next Ten Years and its Main Strengths
14.2 Interview with Dr Ralph Warsinsky, Executive Director of Product Communications at Boehringer Ingelheim
14.2.1 On Boehringer Ingelheim’s Current Biosimilar Pipeline and its Reasons for Entering the Biosimilars Space
14.2.2 On Boehringer Ingelheim’s Track Record with Biopharmaceuticals and the Factors Needed to Become Successful in the Biosimilars Industry
14.2.3 Advantages over Competitors and Thoughts on the US Market
15. Conclusions from Visiongain’s Research and Analysis
15.1 Rapid Growth Expected for this High-Potential Market
15.2 Biosimilar Monoclonal Antibodies to be the Fastest Growing Segment
15.3 A Range of Factors Will Stimulate Demand
15.4 Challenges Remain in Developing and Successfully Launching Biosimilars
【レポート販売概要】
■ タイトル：バイオシミラーおよび後発生物製剤の世界市場動向・研究開発・売上予測：MAbs、融合蛋白質、インスリン、G-CSF、エリトロポエチン、インターフェロン、成長ホルモン、生殖ホルモン■ 英文：Biosimilars and Follow-On Biologics’ Trends, R&D and Revenue Forecasts 2016-2026 : Assess Prospects for MAbs, Fusion Proteins, Insulin, G-CSF, Erythropoietin, Interferons, Growth and Fertility Hormones
■ 発行日：2016年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN6022514
■ 調査対象地域：グローバル
- China Power Investment Corporation：発電所及びSWOT分析2013China Power Investment Corporation - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - …
- 世界のテクニカルセラミックス市場2015The Global Technical Ceramics Industry Report 2015 is a professional and in-depth study on the current state of the Technical Ceramics industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Technical Ceramics market analysis is provided for the international markets including development trends, competiti …
- トゥレット症候群：治療薬の治験動向（2014年下半期）Tourette Syndrome Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Tourette Syndrome Global Clinical Trials Review, H2, 2014" provides data on the Tourette Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tourette Syndrome. It includes an overview of the trial numbers and their recruitment s …
- マイクロ・機械化灌漑システムの世界市場分析：製品別（スプリンクラー、ドリップ、中央ピボット、側方移動）、苗別（プランテーション作物、果樹園作物、畑作物）、用途別、セグメント予測、2014-2025The global micro & mechanized irrigation systems market is expected to reach USD 33.4 billion by 2025, according to a new study by Grand View Research, Inc. The low cost of micro and mechanized irrigation products is expected to fuel the market growth over the forecast period. The cost-saving benefits associated with micro and mechanized irrigation systems, such as chemigation and fertigation, fur …
- Acute Ischemic Stroke：市場分析及び予測（～2017）OpportunityAnalyzer: Acute Ischemic Stroke - Opportunity Analysis and Forecasts to 2017 Summary The acute ischemic stroke (AIS) market is poised for major changes during the forecast window out to 2017. Given the impending patent expiry of Activase/Actilyse, in 2015 and 2016 in the US and 5EU respectively, the current standard of care for AIS patients is expected to lose its leading position. From …
- 胚培養培地の世界市場2017-2021About Embryo Culture IVF is one of the most popular assisted fertility techniques used to treat infertility. IVF involves the fertilization of an egg outside the body; this may be done using eggs and sperm from the couple or donors. IVF is the original test tube baby technique. Once the eggs are fertilized in the laboratory, they are inserted into the uterus for potential implantation. Technavio’s …
- 静電容量式タッチセンサ（非ガラス表面用）の世界市場：プラスチック、ITOフィルム、サファイア、銀ナノワイヤー、グラフェン、メタルメッシュ等In 2012, with the introduction of the first touch-enabled smartphones, iPhone by Apple (U.S.) has triggered the capacitive sensors market immensely. No sooner after this launch, Samsung (South Korea) also entered into this competition by launching the Samsung S5 with the capacitive sensor technology. Rapid technological developments, increasing demand for simple and secured access for users to the …
- Herpes Simplex Infections：グローバル臨床試験レビューH1, 2013Herpes Simplex Infections Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Herpes Simplex Infections Global Clinical Trials Review, H1, 2013" provides data on the Herpes Simplex Infections clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Herpes Simplex Infections. It includes an overview of the trial …
- CMOSイメージセンサーの世界市場The CMOS image sensor market is expected to grow at a CAGR of 11.8% between 2015 and 2020, from USD 9.80 Billion in 2015 to USD 17.1 Billion by 2020. The growth of the market is driven by factors such as the growing implementation of CMOS image sensor in the consumer electronics segment, investment by players to develop CMOS image sensor for automotive sector, and support of 4K pixel technology fo …
- 補助人工心臓（VAD）の世界市場：LVAD、BiVAD、RVADAbout VADs VADs are of three types — LVADs, BiVADs, and RVADs — that are used to treat heart failure. VADs help the weakened heart to pump blood for circulation to other body organs. Surgeons implant these mechanical devices as a treatment option for severe heart conditions such as acute or chronic cardiac functional deterioration and heart failure. Technavio’s analysts forecast the global ventric …
- 世界の建設用シーラント市場2015The Global Construction Sealants Industry Report 2015 is a professional and in-depth study on the current state of the Construction Sealants industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Construction Sealants market analysis is provided for the international markets including development trends, …
- ATMスライドレールの世界市場2016-2020About ATM Slide Rails Slide rails have been an important part of the ATM hardware. They find their application in the pulling out the different mobile components of the ATM hardware components such as cash dispenser unit (CDU), cartridges, error box, deposit box, and also the front panel of the ATM. ATM slide rails come under the business head of the mechanical unit in most of the vendors as these …
- クリーンルーム用ロボットの世界市場2016-2020About the Cleanroom Robots Market A cleanroom is a well-maintained environment with minimum levels of environmental pollutants such as aerosols, dusts, chemicals, and microbes. It has strict specifications about the number of particles per cubic meter and regarding particle size. It is typically used for manufacturing products, which require highly sterile and dust-free environment such as semicon …
- 便座の世界市場2017-2021About Toilet Seats The global toilet seat market is witnessing regional disparities due to cultural differences across the global market. The market focus is shifting to electronic toilet seats from non-electronic toilets seats in the last few years. Japan is one of the leading countries that manufacture high-tech intelligent toilet seats, which experience strong demand from countries such as Chin …
- 世界の永久磁石市場：NdFeB, Ferrite, SmCo, AlnicoRising demand for miniaturization coupled with advancement in technology that leads to the availability of better quality ferrite magnets and neo magnets with lesser dysprosium content, together, will drive the permanent magnets market to $18.8 billion by 2018. Asia-Pacific is the fastest growing markets for permanent magnets. Developing economies such as China and India are act as a growth engine …
